AIM: To investigate the influence of chronic hepatitis B virus (HBV) infection [based on the status of hepatitis B e antigen (HBeAg), HBV DNA, and cirrhosis] on superimposed acute hepatitis E. METHODS: A total of 294 patients were recruited from the Department of Infectious Diseases of the Third Affiliated Hospital, Sun Yat-sen University, from January 2003 to January 2012. The patients were classified into two groups: an HBV + hepatitis E virus (HEV) group (a group with chronic HBV infection that was superinfected with acute hepatitis E, n = 118) and an HEV group (a group with acute hepatitis E, n = 176). We retrospectively analyzed and compared the clinical features of the two groups. Statistical analyses were performed using the χ(2) test or Fisher's exact test for categorical variables and the Student's t test for continuous variables. A P value < 0.05 was considered statistically significant. RESULTS: The peak values of prothrombin time, serum total bilirubin, and Model for End-Stage Liver Disease scores were significantly higher in the HBV + HEV group. More patients in the HBV + HEV group had complications (39.8% vs 16.5%, P = 0.000) and developed liver failure (35.6% vs 8.5%, P = 0.000). Additionally, the mortality of the HBV + HEV group was significantly higher (20.3% vs 7.4%, P = 0.002). Further analysis of the HBV + HEV group showed that there were no significant differences in complication occurrence, liver failure incidence, or mortality between patients with different HBeAg and HBV DNA statuses. However, in patients with underlying cirrhosis, complication occurrence and liver failure incidence significantly increased. In total, 12.7% of the patients in the HBV + HEV group received anti-HBV treatment, but this therapy failed to reduce mortality in patients who developed liver failure. CONCLUSION: The presence of underlying cirrhosis in chronic HBV infection results in more severe clinical outcomes with superimposed acute hepatitis E. Anti-HBV treatment cannot improve the prognosis of liver failure caused by HBV-HEV superinfection.
AIM: To investigate the influence of chronic hepatitis B virus (HBV) infection [based on the status of hepatitis B e antigen (HBeAg), HBV DNA, and cirrhosis] on superimposed acute hepatitis E. METHODS: A total of 294 patients were recruited from the Department of Infectious Diseases of the Third Affiliated Hospital, Sun Yat-sen University, from January 2003 to January 2012. The patients were classified into two groups: an HBV + hepatitis E virus (HEV) group (a group with chronic HBV infection that was superinfected with acute hepatitis E, n = 118) and an HEV group (a group with acute hepatitis E, n = 176). We retrospectively analyzed and compared the clinical features of the two groups. Statistical analyses were performed using the χ(2) test or Fisher's exact test for categorical variables and the Student's t test for continuous variables. A P value < 0.05 was considered statistically significant. RESULTS: The peak values of prothrombin time, serum total bilirubin, and Model for End-Stage Liver Disease scores were significantly higher in the HBV + HEV group. More patients in the HBV + HEV group had complications (39.8% vs 16.5%, P = 0.000) and developed liver failure (35.6% vs 8.5%, P = 0.000). Additionally, the mortality of the HBV + HEV group was significantly higher (20.3% vs 7.4%, P = 0.002). Further analysis of the HBV + HEV group showed that there were no significant differences in complication occurrence, liver failure incidence, or mortality between patients with different HBeAg and HBV DNA statuses. However, in patients with underlying cirrhosis, complication occurrence and liver failure incidence significantly increased. In total, 12.7% of the patients in the HBV + HEV group received anti-HBV treatment, but this therapy failed to reduce mortality in patients who developed liver failure. CONCLUSION: The presence of underlying cirrhosis in chronic HBV infection results in more severe clinical outcomes with superimposed acute hepatitis E. Anti-HBV treatment cannot improve the prognosis of liver failure caused by HBV-HEV superinfection.
Entities:
Keywords:
Acute hepatitis E; Anti-hepatitis B virus treatment; Chronic hepatitis B virus infection; Clinical profile; Superinfection
Authors: Claire Dunn; Maurizia Brunetto; Gary Reynolds; Theodoros Christophides; Patrick T Kennedy; Pietro Lampertico; Abhishek Das; A Ross Lopes; Persephone Borrow; Kevin Williams; Elizabeth Humphreys; Simon Afford; David H Adams; Antonio Bertoletti; Mala K Maini Journal: J Exp Med Date: 2007-03-12 Impact factor: 14.307
Authors: Tae Yeob Kim; Do Seon Song; Hee Yeon Kim; Dong Hyun Sinn; Eileen L Yoon; Chang Wook Kim; Young Kul Jung; Ki Tae Suk; Sang Soo Lee; Chang Hyeong Lee; Tae Hun Kim; Jeong Han Kim; Won Hyeok Choe; Hyung Joon Yim; Sung Eun Kim; Soon Koo Baik; Byung Seok Lee; Jae Young Jang; Jeong Suh; Hyoung Su Kim; Seong Woo Nam; Hyeok Choon Kwon; Young Seok Kim; Sang Gyune Kim; Hee Bok Chae; Jin Mo Yang; Joo Hyun Sohn; Heon Ju Lee; Seung Ha Park; Byung Hoon Han; Eun Hee Choi; Chang H Kim; Dong Joon Kim Journal: PLoS One Date: 2016-01-20 Impact factor: 3.240
Authors: Anthony Brown; John S Halliday; Leo Swadling; Richie G Madden; Richard Bendall; Jeremy G Hunter; James Maggs; Peter Simmonds; Donald B Smith; Louisa Vine; Cara McLaughlin; Jane Collier; David Bonsall; Katie Jeffery; Susanna Dunachie; Paul Klenerman; Jacques Izopet; Nassim Kamar; Harry R Dalton; Eleanor Barnes Journal: Hepatology Date: 2016-10-28 Impact factor: 17.425
Authors: Nghiem Xuan Hoan; Hoang Van Tong; Nicole Hecht; Bui Tien Sy; Patrick Marcinek; Christian G Meyer; Le Huu Song; Nguyen Linh Toan; Jens Kurreck; Peter G Kremsner; C-Thomas Bock; Thirumalaisamy P Velavan Journal: EBioMedicine Date: 2015-11-11 Impact factor: 8.143